{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:59:30Z","timestamp":1776146370712,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Co\u2010infection with tuberculosis (TB) is the leading cause of death in individuals infected with human immunodeficiency virus (HIV)\u20101. Dolutegravir and lamivudine (DTG\u2009+\u20093TC) has recently been recommended as the preferred first\u2010line regimen for the treatment of new and treatment\u2010experienced HIV\u2010infected patients. The primary objective of this study was to determine the efficacy and safety of DTG (50\u2009mg)\u2009+\u20093TC (300)\u2009mg in HIV\u2010positive antiretroviral therapy (ART)\u2010na\u00efve patients with TB who received a rifampicin\u2010 or rifabutin\u2010based treatment regimen and characterize viral suppression rates at week 48.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single\u2010center retrospective observational case series, spanning January 1, 2021 to March 1, 2023, was conducted in Guiyang Public Health Treatment Center. Of 46 TB\/HIV co\u2010infected patients received DTG\u2009+\u20093TC or DTG\/3TC, a total of 42 patients were finally enrolled in the study. The outcomes of interest were successful TB treatment, viral load (VL) suppression, and immunological and biochemical indexes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All people with HIV infection (PWH) underwent at least 48 weeks of follow\u2010up; all TB treatments were successful. A total of seven PWH (100%) achieved viral suppression (VL\u2009&lt;\u200950 copies\/mL) from a baseline VL greater than 500,000 copies\/mL. Among the PWH who started DTG\u2009+\u20093TC after initiating the rifabutin\u2010based anti\u2010TB regimen, 31 (73.8%) achieved viral suppression by week 24. CD4\u2009+\u2009T\u2010cell counts were greatly improved after antiretroviral treatment. The CD4\u2009+\u2009\/CD8+ ratio increased by 0.38 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Total cholesterol, and high\u2010density lipoprotein cholesterol (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). There were no significant changes in body mass index, low\u2010density lipoprotein cholesterol, and triglyceride levels from baseline to week 48 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). No serious adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case series preliminarily validated the efficacy of DTG\u2009+\u20093TC when combined with rifabutin\u2010based anti\u2010TB regimens in patients with TB and HIV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/iid3.70381","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T02:56:13Z","timestamp":1774234573000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Dolutegravir Plus Lamivudine in People With TB\/HIV Co\u2010Infection Using a Rifampicin or Rifabutin\u2010Based Regimen: A Retrospective Observational Case Series"],"prefix":"10.1002","volume":"14","author":[{"given":"Jinhong","family":"He","sequence":"first","affiliation":[{"name":"Infection Department Guiyang Public Health Clinical Center Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangxi","family":"He","sequence":"additional","affiliation":[{"name":"Infection Department Guiyang Public Health Clinical Center Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxin","family":"Xie","sequence":"additional","affiliation":[{"name":"Infection Department Guiyang Public Health Clinical Center Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Fu","sequence":"additional","affiliation":[{"name":"Infection Department Guiyang Public Health Clinical Center Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxing","family":"Luo","sequence":"additional","affiliation":[{"name":"Infection Department Guiyang Public Health Clinical Center Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinshuang","family":"Peng","sequence":"additional","affiliation":[{"name":"Infection Department Guiyang Public Health Clinical Center Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[{"name":"Infection Department Guiyang Public Health Clinical Center Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-5623","authenticated-orcid":false,"given":"Hai","family":"Long","sequence":"additional","affiliation":[{"name":"Infection Department Guiyang Public Health Clinical Center Guiyang Guizhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/424851"},{"key":"e_1_2_11_3_1","unstructured":"AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association; Chinese Center for Disease Control and Prevention.Zhonghua Nei Ke Za Zhi.2021;60(12):1106\u20101128 https:\/\/doi.org\/10.3760\/cma.j.cn112138-20211006-00676."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e010c"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.J.c.n112338-20240311-00111"},{"key":"e_1_2_11_6_1","unstructured":"World Health Organization.WHO recommends dolutegravir as preferred HIV treatment option in all populations accessed July 30 2020."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.13419\/j.cnki.aids.2023.05.03"},{"key":"e_1_2_11_9_1","unstructured":"EACS Secretariat EACS Guidelines Version 11.0. [(accessed on 09 July 2024)]. Available online:https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf."},{"key":"e_1_2_11_10_1","unstructured":"L.Yanjun liXueqin O.Ruzhi L.Huan Q.Yingmei andX.Zhiman.The Fourth People's Hospital of Nanning Nanning China."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.12.069"},{"key":"e_1_2_11_12_1","unstructured":"T. S.NationalClinical Practice Guideline on the Diagnosis Treatment and Prevention of Tuberculosis[J]. [2024\u201003\u201024]. Available online:https:\/\/xueshu.baidu.com\/usercenter\/paper\/show?paperid=69690c4a809903ea34e4ae1c70b69124&site=xueshu_se."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038558"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.01.21678"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01842-3"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60084-2"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04440.x"},{"key":"e_1_2_11_18_1","unstructured":"Cahn et al.IAS2019; Mexico City Mexico. Slides WEAB0404LB."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes14061214"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002126"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.70381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/iid3.70381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.70381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:17:17Z","timestamp":1776143837000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.70381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/iid3.70381"],"URL":"https:\/\/doi.org\/10.1002\/iid3.70381","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2024-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70381"}}